Zevra Therapeutics, Inc. Lease Obligation Incurred
Zevra Therapeutics, Inc. (ZVRA) reported Lease Obligation Incurred of $52.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2019-03-01
- Zevra Therapeutics, Inc. lease obligation incurred for the quarter ending 2018-12-31 was $0.00.
- Zevra Therapeutics, Inc. lease obligation incurred for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. lease obligation incurred for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. lease obligation incurred for the quarter ending 2017-06-30 was $54.00K.
- Zevra Therapeutics, Inc. lease obligation incurred for fiscal 2018 was $52.00K, a 81.69% decline from fiscal 2017.
- Zevra Therapeutics, Inc. lease obligation incurred for fiscal 2017 was $284.00K, a 67.24% decline from fiscal 2016.
- Zevra Therapeutics, Inc. lease obligation incurred for fiscal 2016 was $867.00K.
- Zevra Therapeutics, Inc. lease obligation incurred for fiscal 2013 was $94.00K.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 6 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $52.00K 10-K · filed 2019-03-01 | ||
| 2018-09-30 | $52.00K 10-Q · filed 2018-11-09 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $54.00K derived: sum of 3 quarters · filed 2019-03-01 | $284.00K 10-K · filed 2019-03-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $54.00K derived: sum of 2 quarters · filed 2018-11-09 | $284.00K 10-Q · filed 2018-11-09 | $555.00K derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $284.00K 10-Q · filed 2018-08-10 | $555.00K derived: sum of 3 quarters · filed 2018-08-10 | $603.00K derived: sum of 4 quarters · filed 2018-08-10 |
| 2017-03-31 | $230.00K 10-Q · filed 2018-05-11 | $501.00K derived: sum of 2 quarters · filed 2018-05-11 | $549.00K derived: sum of 3 quarters · filed 2018-05-11 | |
| 2016-12-31 | $271.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $319.00K derived: sum of 2 quarters · filed 2018-03-30 | $867.00K 10-K · filed 2018-03-30 | |
| 2016-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $596.00K 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $548.00K 10-Q · filed 2017-08-10 | |||
| 2015-06-30 | $42.00K 10-Q · filed 2016-08-11 | |||
| 2013-12-31 | $94.00K 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |